5-Amino-1-MQ: NNMT Inhibitor and Metabolic Pathway Guide

By Justin Cartier

For the wider context, see our overview of research peptides for weight loss.

5-Amino-1MQ is a small molecule that blocks an enzyme called NNMT. In obese mice, that one move lowers body weight, shrinks fat cells, and sharpens insulin sensitivity. Here’s the thing to get straight up front: it isn’t a peptide. It works inside the fat cell itself, not on a surface receptor the way GLP-1 drugs or growth hormone peptides do. It’s sold for laboratory research only.

This guide covers what 5-Amino-1MQ actually does in metabolic research, how blocking NNMT rewires the way a fat cell handles energy, what the mouse obesity studies show on fat loss, how it stacks up against the peptide options, and what to check when you source it. Every key claim links to a peer-reviewed source.

Research-use disclaimer: 5-Amino-1MQ is sold for laboratory research only. It is not a drug or supplement and is not for human use.

What is 5-Amino-1MQ used for?

At its core, it’s a chemical probe for studying the NNMT pathway in metabolic disease. Researchers reach for it in rodent obesity models, in fatty-liver experiments, in studies of fat-tissue energy metabolism, and in age-related metabolic decline work. It’s research-use-only, with no approval from Health Canada or the FDA for anything therapeutic. So don’t think of it as a drug candidate. Think of it as a molecular tool, one that lets researchers isolate exactly what NNMT is contributing to metabolic trouble in a living animal.

What is NNMT and why does inhibiting it matter?

NNMT is short for nicotinamide N-methyltransferase. It moves a methyl group from a molecule called SAM onto nicotinamide. That spits out 1-methylnicotinamide and a byproduct. In fat tissue and liver, the reaction quietly drains two things the cell needs: SAM itself and the raw material for NAD+. Metabolic researchers call it a “futile cycle,” because it burns through methyl groups that could be doing useful work elsewhere. Kraus and colleagues, in Nature, showed NNMT runs high in the fat and liver of obese, diabetic mice, which flags the enzyme as a driver of the problem rather than an innocent bystander.^[1]

So what happens when you block it? The drain reverses. SAM builds back up for productive methylation, and nicotinamide gets funneled into making NAD+ instead of being wasted. A 2021 review of NNMT in obesity and type 2 diabetes ties that same shift to a real jump in whole-body energy expenditure, lower body weight, and restored insulin sensitivity, all without touching a single receptor.^[4]

Mechanism of action of 5-Amino-1MQ

Structurally, 5-Amino-1MQ is a methylquinolinium scaffold with a small amine tacked on. That little amine is what lets it slip across the cell membrane. Neelakantan and colleagues, in Biochemical Pharmacology, picked it as the lead from a whole series of analogues. They chose it for its mix of NNMT potency, membrane permeability, and selectivity over other methyltransferases.^[2] It works by sitting in the nicotinamide-binding pocket of NNMT and blocking the substrate from getting in, no covalent bonding, just competition for the spot.

Once NNMT is inhibited, the fat cell’s chemistry tips over. SAM piles up, its byproduct drops, and more nicotinamide flows back into NAD+. And that cascade flips on the good stuff. Markers of mitochondrial function climb. Thermogenic genes fire up, UCP1 among them, in the beige fat depots. And measurable cellular energy expenditure goes up. Zoom out to the whole animal and it shows up as smaller fat cells under the microscope, less fat mass, and steadier blood sugar.

Body composition and fat loss data

The most repeatable fat-loss signal comes from diet-induced obese (DIO) mouse models. A 2024 study in Diabetes, Obesity and Metabolism found that 5-Amino-1MQ cut body-weight gain and fat-mass accumulation in a dose-dependent way versus vehicle controls.^[3] And a 2022 study in Scientific Reports logged a striking drop in whole-body fat and weight in DIO mice over the usual 4-to-8-week preclinical window.^[5]

Here’s a data point worth flagging. In the Neelakantan medicinal-chemistry work, the lead compound meaningfully shrank fat-cell size in obese mice and pulled down total body fat, and it did that without eating into muscle mass on tissue analysis.^[2] That fat-specific selectivity is a big part of why NNMT inhibition is seen as mechanistically different from plain calorie restriction, where you tend to lose some muscle along with the fat.

The secondary wins line up nicely across studies, too: less fat stored in the liver, lower fasting insulin, better HOMA-IR scores, and more thermogenic activity in brown fat. What’s satisfying is that one mechanism, conserving SAM and NAD+, explains every one of those endpoints.

How long does it take to see results?

In the rodent work, the body-weight curves start pulling away from controls within 2 to 4 weeks at standard doses. Fat-mass differences usually hit statistical significance by week 6 to 8, and insulin sensitivity improves on roughly the same clock. But here’s the honest caveat: there’s no validated human timeline. As of 2026, no completed human trial of 5-Amino-1MQ for obesity or body composition has been published, so none of these numbers translate cleanly to people.

5-Amino-1MQ vs peptide weight-loss interventions

It’s worth spelling out that 5-Amino-1MQ isn’t a peptide and doesn’t really compete with the peptide options on mechanism. GLP-1 receptor agonists like semaglutide, tirzepatide, and retatrutide curb appetite and slow the stomach through incretin receptors. AOD-9604 acts as a lipolytic fragment at the beta-3 adrenergic receptor. Tesamorelin drives visceral fat loss through GHRH signalling. 5-Amino-1MQ, by contrast, works inside the cell, on the methyl-group economy of the fat cell. Because those pharmacology classes hit completely separate pathways, researchers sometimes combine them to probe whether the effects add up or amplify. That’s the scientific logic behind multi-compound study designs, not a therapeutic recommendation.

Dosing and routes of administration in research

Published rodent studies give 5-Amino-1MQ by intraperitoneal injection or oral gavage, somewhere in the 10 to 50 mg/kg/day range. One practical edge is that it’s orally bioavailable, which peptide interventions usually aren’t since they need injecting. Standard preclinical dosing runs 4 to 12 weeks. There’s no human pharmacokinetic data on record, and no validated way to convert the rodent dosage to a human one.

Side effects and safety in preclinical data

So far, rodent toxicology at standard doses hasn’t turned up liver, heart, or kidney toxicity. Body composition shifts leaner without any reported muscle wasting. The one theoretical worry is off-target methyltransferase inhibition. Any small molecule that plugs the nicotinamide site on one enzyme could, in principle, nudge related ones. The published selectivity profiles for 5-Amino-1MQ look acceptable on that front, but long-term toxicology simply hasn’t been finished, and human safety data is entirely absent. Worth keeping both of those caveats front of mind.

Legal status

5-Amino-1MQ falls under research-chemical rules in Canada and the US, carrying research-use-only labelling. Health Canada and the FDA haven’t approved it for anything therapeutic. It doesn’t appear on the World Anti-Doping Agency banned list as of 2026, though athletes under WADA jurisdiction should track the updates themselves.

5-Amino-1MQ sells legally in Canada as a research chemical, and our guide to the Canadian legal framework for buying peptides lays out the rules that apply.

Available forms and sourcing

Everything you measure with 5-Amino-1MQ is an enzyme-inhibition readout, whether that is NNMT activity, IC50 values, or SAM and NAD+ levels, and those numbers only mean something if the molecule in the vial is exactly this compound. It is a small methylquinolinium, and a close structural analogue could inhibit NNMT with different potency or spill over onto related methyltransferases, quietly shifting your IC50 and selectivity data. So confirm the identity before you run the assay. Ask for mass spectrometry matching the expected molecular weight of 175.21 g/mol and HPLC purity of 98 percent or higher, backed by a batch-specific Certificate of Analysis. You will find it supplied as a powder or an oral capsule, and because it is a small molecule rather than a peptide it is more stable on the shelf, so short-term transport does not need the cold-chain shipping peptides do.

Reviv Peptides supplies 5-Amino-1MQ in research-grade format with COA and HPLC purity confirmation. View the 5-Amino-1MQ product page.

5-Amino-1MQ questions

What is 5-Amino-1MQ used for?

It’s used in research as a chemical probe for the NNMT pathway in obesity, fat loss, fatty-liver disease, and aging biology. It isn’t approved for any human use and is sold for research only.

What is the mechanism of action of 5-Amino-1MQ?

It competitively inhibits nicotinamide N-methyltransferase (NNMT) at the nicotinamide-binding pocket. That conserves SAM and NAD+ in the fat cell, which lifts thermogenic gene expression, mitochondrial function, and cellular energy expenditure, and the net result in rodent obesity models is less fat mass and better insulin sensitivity.

What are the side effects and safety considerations of 5-Amino-1MQ?

Preclinical rodent data shows no liver or heart toxicity at standard doses. Off-target methyltransferase inhibition is the main theoretical risk, though published selectivity looks acceptable. Long-term toxicology is incomplete, and human safety data is absent.

How long does it take to see results from 5-Amino-1MQ?

In rodent studies, body weight pulls away from controls within 2 to 4 weeks, and fat-mass differences reach significance by 6 to 8 weeks. There’s no human timeline, since no completed human trial has been published.

What is the legal status of 5-Amino-1MQ?

It falls under research-chemical rules in Canada and the US, carrying research-use-only labelling. It isn’t approved for any therapeutic use and doesn’t appear on the WADA banned list as of 2026.

Summary

5-Amino-1MQ is the best-validated small-molecule probe for the NNMT pathway in obesity and metabolic health research. It lowers body weight, fat mass, and fat-cell size in DIO mouse models, improves insulin sensitivity, and raises cellular energy expenditure, all through the fat cell’s methyl-group economy rather than any receptor signal. It isn’t a peptide, isn’t approved for human use, and has no completed human trial data behind it. For anyone studying metabolic dysfunction through the NNMT axis, it’s the reference compound in its scaffold class.

Sources

Sources: [1] NNMT raised in obese/diabetic tissue (Kraus et al., Nature 2014), PubMed/NIH. [2] Selective, membrane-permeable NNMT inhibitors (Neelakantan et al., Biochem Pharmacol 2018), PubMed/NIH. [3] NNMT inhibition mitigates obesity-related metabolic dysfunction (2024), PubMed/NIH. [4] Roles of NNMT in obesity and type 2 diabetes (review, 2021), PubMed/NIH. [5] Reduced-calorie diet combined with NNMT inhibition (Sci Rep 2022), PubMed/NIH.